Gilead Just Spent $13 Billion in Six Weeks. What Do They Know?
Gilead Sciences just closed its third acquisition in six weeks, bringing its recent M&A tab to nearly $13 billion. The latest buy: a German ADC biotech that could reshape how cancer drugs find their targets.
Three Deals, Six Weeks, One Very Busy Checkbook
Most pharma companies announce one big acquisition and spend the rest of the year digesting it. Gilead Sciences just made three in about six weeks, spending nearly $13 billion in the process. The latest target: Tubulis, a German biotech specializing in antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in milestone payments.
The deal, announced April 7, isn't just big. It's the final piece of a buying spree that looks less like corporate strategy and more like someone panic-shopping before a store closes.
So what does Gilead know that the rest of us don't?
The Shopping List
Let's rewind. In late February, Gilead kicked things off by acquiring Arcellx for $7.8 billion, picking up a next-generation CAR-T cell therapy (a treatment that reprograms a patient's own immune cells to fight cancer) called anito-cel. That drug is already under FDA review for relapsed multiple myeloma, meaning it could hit the market relatively soon.
Then in March, Gilead grabbed Ouro Medicines for $1.675 billion upfront (up to $2.175 billion including milestones), landing a clinical-stage drug called gamgertamig for autoimmune diseases like hemolytic anemia and immune thrombocytopenia. A slight detour from oncology, but still within Gilead's broader playbook of diversifying beyond its HIV bread and butter.
And now, Tubulis. Three deals totaling roughly $13 billion since late February 2026. That's not a strategy refresh; that's a full-blown identity makeover.
Why ADCs Are the Hottest Ticket in Oncology
To understand the Tubulis deal, you need to understand why everyone in pharma is obsessed with antibody-drug conjugates right now. Think of an ADC like a guided missile: you attach a toxic cancer-killing payload to an antibody that knows exactly which cells to target. The antibody finds the tumor, locks on, and delivers its poison directly, sparing healthy tissue (at least in theory).
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The concept has been around for decades, but the technology has finally matured. Pfizer paid $43 billion for Seagen back in 2023 to become the ADC market leader. AbbVie inked a $5.6 billion deal with RemeGen in early 2026 for a bispecific antibody (RC148) that complements its broader ADC strategy. AstraZeneca has committed up to approximately $12.9 billion across its partnerships with Daiichi Sankyo on multiple ADC programs.
When you see numbers like that, Gilead's urgency starts making a lot more sense.
What Makes Tubulis Special
Tubulis isn't just another ADC company. Its proprietary conjugation platform (the tech that connects the antibody to its toxic payload) is designed to create more stable, less toxic ADCs. If standard ADCs are guided missiles, Tubulis is building ones that don't leak fuel on the way to the target.
That matters because toxicity has been the Achilles' heel of the ADC field. Payloads can detach prematurely, causing side effects in healthy tissue. Tubulis claims its technology keeps the drug locked in place until it reaches the tumor, improving the "therapeutic index" (the gap between a dose that works and a dose that harms).
The company's lead asset, TUB-040, is in Phase 1b/2 trials for platinum-resistant ovarian cancer and non-small cell lung cancer. Early data reportedly showed a 59% objective response rate in ovarian cancer, which analysts are calling potentially best-in-class. A second drug, TUB-030, targets solid tumors and has promising early clinical data as well.
Gilead and Tubulis aren't strangers, either. The two companies started collaborating back in 2024, with Gilead initially paying $20 million upfront and committing up to $415 million in milestones. This acquisition is basically Gilead saying, "We've seen enough. We're buying the whole restaurant, not just ordering appetizers."
Post-close, Tubulis will become Gilead's dedicated ADC research hub in Munich, handling discovery, manufacturing, and clinical development from Europe.
Gilead's ADC Report Card So Far
Gilead isn't starting from zero in the ADC space. It already owns Trodelvy (sacituzumab govitecan), a Trop-2-directed ADC it picked up through the Immunomedics acquisition. Trodelvy has been a mixed bag lately.
On the wins side: the ASCENT-03 trial showed Trodelvy reduced the risk of disease progression or death by 38% versus chemotherapy in first-line metastatic triple-negative breast cancer patients. The ASCENT-04 trial, combining Trodelvy with Merck's Keytruda, also hit its primary endpoint.
On the losses side: the ASCENT-07 trial completely whiffed in HR+/HER2- breast cancer, with identical median progression-free survival (8.3 months) in both the treatment and control groups. That's like training for a marathon and finishing in a dead tie with someone who walked.
So Trodelvy is a solid asset in certain cancers but clearly has limits. Tubulis gives Gilead a next-generation platform to build ADCs that could succeed where Trodelvy stumbles, particularly in solid tumors that remain notoriously hard to treat.
Wall Street's Verdict: Cautiously Enthusiastic
Analysts are largely on board with the deal. BMO Capital reiterated an Outperform rating with a $174 price target, suggesting about 25% upside from the ~$139 share price at the time of the announcement. Cantor Fitzgerald and Oppenheimer both maintained bullish ratings as well.
The consensus view: Gilead is smartly shifting from licensing ADC technology to owning the platform outright, which gives it more control over the science and more of the economics. Instead of paying royalties to a partner, Gilead now controls the entire discovery-to-clinic pipeline.
Not everyone is fully convinced, though. At least one analyst flagged execution risk as a concern, and rightfully so. Integrating three acquisitions in six weeks is like renovating three houses simultaneously; something is bound to go over budget or behind schedule.
The Bigger Picture
Zoom out and the story becomes clear. Gilead built its empire on HIV drugs like Biktarvy and hepatitis C cures like Sovaldi. Those franchises still generate enormous cash flow, but they won't grow forever. The company needs new engines, and it's betting that oncology (and to a lesser extent, autoimmune disease) will be those engines.
With nearly $13 billion deployed in six weeks across CAR-T therapy, bispecific antibodies, and ADCs, Gilead is assembling one of the most diverse oncology toolkits in pharma. CEO Daniel O'Day has emphasized addressing unmet needs in solid tumors and blood cancers.
The risk? Gilead is paying top dollar for clinical-stage assets, not approved drugs. TUB-040 could flame out in later trials. Anito-cel could face a rocky FDA review. These are expensive bets on outcomes that aren't guaranteed.
But in a world where $200 billion in pharma revenue faces patent cliffs by 2030, standing still might be the riskiest move of all. Gilead is clearly choosing to run.
Deals & M&A4 min read
Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of
Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.
